Viridian Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing total revenues of $141,000, a significant increase from $72,000 in the same period of 2025. The revenue growth was primarily driven by a $6,000 license revenue from a collaboration agreement with Kissei Pharmaceutical and a $135,000 increase in collaboration revenue from related parties. Despite this revenue growth, the company incurred a net loss of $104.9 million, compared to a net loss of $86.9 million in the prior year, reflecting a 20.7% increase in losses year-over-year.
Operating expenses for the quarter totaled $116.3 million, up from $93.9 million in the first quarter of 2025. This increase was largely attributed to a rise in selling, general, and administrative expenses, which surged to $38.7 million from $17.1 million, driven by higher personnel costs and increased legal and consulting fees associated with preparatory commercial activities for its product candidates. Research and development expenses remained relatively stable, totaling $77.6 million, compared to $76.8 million in the previous year.
In terms of operational developments, Viridian is advancing its product pipeline, particularly focusing on its lead candidates, veligrotug and elegrobart, for the treatment of thyroid eye disease (TED). The company is currently conducting pivotal phase 3 clinical trials for both products, with topline data from the REVEAL-1 study indicating a statistically significant treatment effect. The company anticipates submitting a Biologics License Application (BLA) for elegrobart in the first quarter of 2027, following the expected BLA submission for veligrotug in June 2026.
As of March 31, 2026, Viridian reported cash, cash equivalents, and marketable securities totaling $762.2 million, a decrease from $894.2 million at the end of 2025. The company expects its current financial resources to sustain operations for at least the next twelve months. However, it acknowledged the potential need for additional capital to support ongoing research and development activities, particularly as it prepares for the commercialization of its product candidates, pending regulatory approvals.
Looking ahead, Viridian remains focused on its strategic initiatives to enhance its clinical and commercial capabilities. The company is also navigating a challenging macroeconomic environment, which could impact its operations and funding strategies. Despite the uncertainties, Viridian is committed to advancing its therapeutic programs and achieving key regulatory milestones to drive future revenue growth.
About Viridian Therapeutics, Inc.DE
Viridian Therapeutics is a biopharmaceutical company developing innovative biologic medicines for serious and rare diseases, primarily focusing on thyroid eye disease (TED). Its pipeline includes monoclonal antibodies targeting IGF-1R and engineered FcRn inhibitors to improve efficacy, safety, and convenience. The company aims to address unmet medical needs, advance clinical trials globally, and secure regulatory approvals for differentiated therapies in autoimmune and ophthalmic conditions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.